IFP Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $843K | Sell |
1,352
-116
| -8% | -$79K | 0.02% | 808 |
|
|
2026
Q1 | $1.13M | Sell |
1,468
-26
| -2% | -$19.9K | 0.02% | 637 |
|
|
2025
Q4 | $1.15M | Buy |
1,494
+91
| +6% | +$61.8K | 0.03% | 596 |
|
|
2025
Q3 | $789K | Buy |
1,403
+173
| +14% | +$97.8K | 0.02% | 698 |
|
|
2025
Q2 | $646K | Buy |
1,230
+206
| +20% | +$115K | 0.02% | 734 |
|
|
2025
Q1 | $649K | Buy |
1,024
+656
| +178% | +$451K | 0.02% | 695 |
|
|
2024
Q4 | $262K | Buy |
368
+54
| +17% | +$45.3K | 0.01% | 1008 |
|
|
2024
Q3 | $329K | Sell |
314
-237
| -43% | -$264K | 0.01% | 861 |
|
|
2024
Q2 | $578K | Buy |
551
+46
| +9% | +$44.6K | 0.02% | 613 |
|
|
2024
Q1 | $486K | Buy |
505
+16
| +3% | +$15.2K | 0.02% | 619 |
|
|
2023
Q4 | $430K | Buy |
489
+47
| +11% | +$38.7K | 0.02% | 630 |
|
|
2023
Q3 | $364K | Buy |
442
+39
| +10% | +$30.7K | 0.02% | 706 |
|
|
2023
Q2 | $290K | Buy |
403
+44
| +12% | +$33.9K | 0.01% | 850 |
|
|
2023
Q1 | $110K | Sell |
359
-741
| -67% | -$559K | ﹤0.01% | 1209 |
|
|
2022
Q4 | $364K | Sell |
1,100
-443
| -29% | -$327K | 0.01% | 1041 |
|
|
2022
Q3 | $589K | Buy |
1,543
+64
| +4% | +$40.3K | 0.02% | 846 |
|
|
2022
Q2 | $561K | Hold |
1,479
| – | – | 0.02% | 795 |
|
|
2022
Q1 | $561K | Buy |
1,479
+1,028
| +228% | +$650K | 0.02% | 795 |
|
|
2021
Q4 | $285K | Sell |
451
-70
| -13% | -$43K | 0.01% | 800 |
|
|
2021
Q3 | $313K | Buy |
521
+16
| +3% | +$9.93K | 0.01% | 752 |
|
|
2021
Q2 | $283K | Buy |
505
+202
| +67% | +$102K | 0.01% | 746 |
|
|
2021
Q1 | $140K | Buy |
303
+32
| +12% | +$15.6K | ﹤0.01% | 1000 |
|
|
2020
Q4 | $126K | Buy |
271
+90
| +50% | +$48.6K | 0.01% | 1017 |
|
|
2020
Q3 | $101K | Buy |
181
+19
| +12% | +$11.5K | 0.01% | 993 |
|
|
2020
Q2 | $102K | Sell |
162
-15
| -8% | -$8.51K | 0.01% | 920 |
|
|
2020
Q1 | $80K | Buy |
+177
| New | +$73K | 0.01% | 929 |
|
|
2019
Q4 | – | Sell |
-2,208
| Closed | -$743K | – | 3072 |
|
|
2019
Q3 | $598K | Buy |
+2,208
| New | +$653K | 0.04% | 447 |
|
|
2019
Q1 | $10K | Sell |
25
-264
| -91% | -$109K | ﹤0.01% | 1610 |
|
|
2018
Q4 | $105K | Sell |
289
-29
| -9% | -$10.6K | 0.01% | 1165 |
|
|
2018
Q3 | $128K | Buy |
318
+10
| +3% | +$3.81K | 0.01% | 1335 |
|
|
2018
Q2 | $106K | Buy |
308
+57
| +23% | +$17.8K | ﹤0.01% | 1445 |
|
|
2018
Q1 | $94K | Hold |
251
| – | – | ﹤0.01% | 1421 |
|
|
2017
Q4 | $94K | Sell |
251
-140
| -36% | -$56.7K | ﹤0.01% | 1433 |
|
|
2017
Q3 | $175K | Buy |
391
+6
| +2% | +$2.85K | 0.01% | 1220 |
|
|
2017
Q2 | $189K | Buy |
385
+96
| +33% | +$42K | 0.01% | 1157 |
|
|
2017
Q1 | $112K | Sell |
289
-13
| -4% | -$4.82K | ﹤0.01% | 1426 |
|
|
2016
Q4 | $111K | Sell |
302
-58
| -16% | -$22.1K | 0.01% | 1394 |
|
|
2016
Q3 | $145K | Buy |
360
+32
| +10% | +$12.8K | 0.01% | 1156 |
|
|
2016
Q2 | $115K | Buy |
328
+303
| +1,212% | +$117K | 0.01% | 1252 |
|
|
2016
Q1 | $10K | Sell |
25
-558
| -96% | -$230K | ﹤0.01% | 1608 |
|
|
2015
Q4 | $316K | Buy |
+583
| New | +$316K | 0.02% | 639 |
|
Other funds holding REGN
IFP Advisors's REGN Position: Q2 2026 in Review
IFP Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 7.9% in Q2 2026, selling an estimated $79K and leaving 1,352 shares worth $843K. The position accounts for 0.02% of the portfolio, ranked #808.
IFP Advisors first reported a position in REGN in Q4 2015 and has held it in 41 quarters since. The position peaked at $1.15M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- IFP Advisors held 1,352 shares of Regeneron Pharmaceuticals worth $843K as of Q2 2026.
- IFP Advisors sold 116 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $79K.
- Regeneron Pharmaceuticals made up 0.02% of IFP Advisors's portfolio in Q2 2026, its #808 holding.
- IFP Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 41 quarters since.
- IFP Advisors's Regeneron Pharmaceuticals position peaked at $1.15M in Q4 2025.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.